CHRISTINA DARLING: Open Payments
NPI 1083181432 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$507 in 15 payments from 9 companies in 2025. Trend: 2023 $551 · 2024 $450 · 2025 $507
Food & beverage: $507
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 1 | $111 |
| AstraZeneca Pharmaceuticals LP | 1 | $96 |
| ABBVIE INC. | 5 | $86 |
| Novo Nordisk Inc | 1 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: REXULTI, BREZTRI, Ozempic, CAPLYTA, UBRELVY, VRAYLAR, HETLIOZ, GARDASIL 9.
Industry payments across MD — which companies pay providers there.
